Home > Oncology > ELCC 2022 > Small Cell Lung Cancer > Characteristics of long-term survivors in the CASPIAN trial

Characteristics of long-term survivors in the CASPIAN trial

Presented By
Dr Niels Reinmuth, Asklepios Lung Clinic, Germany
Presented by
Niels Reinmuth Asklepios Lung Clinic, Germany
Conference
ELCC 2022
Trial
Phase 3, CASPIAN
Doi
https://doi.org/10.55788/d3d098bf
Long-term survivors in the CASPIAN trial share common favourable – and potentially predictive – clinical and molecular characteristics. This was demonstrated in a subanalysis of the phase 3 trial investigating durvalumab in extensive-stage small cell lung cancer (ES-SCLC). Recently, the phase 3 CASPIAN trial (NCT03043872) demonstrated improved overall survival (OS) with durvalumab plus platinum-etoposide (EP) versus EP alone as first-line treatment of ES-SCLC [1,2]. A numerical improvement in OS was observed with durvalumab plus tremelimumab plus EP versus EP alone. This benefit was sustained with more than 3 years follow-up [3]. As biomarkers that predict the efficacy of immune checkpoint blockade have not been well characterised in SCLC, clinical and molecular characteristics of patients who experienced long-term survival in CASPIAN were assessed. Dr Niels Reinm...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on